Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | CLK3 | P49761 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24573624 | 1.00 | NPBWR1 (0.37) | NPBWR1EGFRCLK2CLK3DYRK1A | |
| SCHEMBL24573606 | 0.91 | NPBWR1 (0.37) | NPBWR1EGFR | |
| SCHEMBL30248821 | 0.90 | NPBWR1 (0.32) | NPBWR1EGFRCLK2CLK3DYRK1A | |
| SCHEMBL24573584 | 0.90 | NPBWR1 (0.32) | NPBWR1EGFRCLK2CLK3DYRK1A | |
| SCHEMBL30248641 | 0.89 | NPBWR1 (0.36) | NPBWR1 | |
| SCHEMBL24573134 | 0.89 | NPBWR1 (0.36) | NPBWR1 | |
| SCHEMBL29735024 | 0.87 | NPBWR1 (0.35) | NPBWR1 | |
| SCHEMBL24573627 | 0.87 | NPBWR1 (0.35) | NPBWR1 | |
| SCHEMBL24573636 | 0.86 | NPBWR1 (0.35) | NPBWR1 | |
| SCHEMBL29735020 | 0.86 | NPBWR1 (0.35) | NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635382-A | Indole derivatives useful for treating cGAS-related disorders | 诺华股份有限公司 | 2023-08-22 | — | — | CN | claimed |
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | NOVARTIS AG (CH) | 2025-09-02 | — | — | US | disclosed |
| CN-116635382-A | Indole derivatives useful for treating cGAS-related disorders | 诺华股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | NOVARTIS PHARMA AG (CH) | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | CGAS, TDP1, IAPP | NPBWR1 1696/4885EGFR 4104/4885CLK2 1372/4885 |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | CGAS, TDP1, IAPP | NPBWR1 1696/4885EGFR 4104/4885CLK2 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.